Phase II Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...